Sanara MedTech Earnings Call Transcripts
Fiscal Year 2026
-
Shareholders approved the merger with MiMedx and the related executive compensation proposal. A quorum was present, and all proposals received majority support. Final results will be reported in a Form 8-K filing.
-
The meeting covered director elections, auditor ratification, and advisory votes on executive compensation and its voting frequency. All proposals passed, with directors elected, auditor ratified, compensation approved, and a three-year advisory vote frequency set.
-
Q1 2026 delivered 19% revenue growth and a return to GAAP net profitability, driven by strong sales of core surgical products and expanded market presence. Guidance for 2026 was reaffirmed, with continued investment in sales and R&D supporting long-term growth.
-
The company has transitioned to a pure-play surgical wound care focus, achieving strong revenue growth and expanding its reach to over 4,000 facilities. With three core technologies and a robust commercial strategy, it projects continued double-digit growth, stable margins, and new product launches through 2027.
Fiscal Year 2025
-
Record 2025 revenue of $103.1M (up 19% YoY) and 93% gross margin reflect strong execution and focus on surgical markets. 2026 guidance projects 13–17% revenue growth, with new Vizient contract and clinical evidence supporting further expansion.
-
Q3 2025 saw 22% revenue growth, margin expansion, and strong operating leverage, driven by core surgical products. THP operations were discontinued to focus on the surgical segment, with continued investment in product innovation and commercial expansion.
-
Leadership transitions and a broadened management team are driving operational discipline and growth. Strong Q2 results were fueled by balanced product performance and expanded distributor reach, while new products and strategic alternatives for THP signal continued innovation and market expansion.
-
Q2 2025 saw 28% revenue growth, improved profitability, and strong cash flow, led by the surgical segment. Strategic alternatives are being explored for THP, with reduced investment planned. The company remains focused on growth, innovation, and capital preservation.
-
Q1 2025 saw 26% revenue growth, margin expansion, and strong execution in both business segments. The company launched the THP Copilot platform, expanded its distributor network, and remains focused on profitability and strategic investments.
Fiscal Year 2024
-
Net revenue grew 33% to $86.7M in 2024, with strong gains in soft tissue products and positive Adjusted EBITDA. The company expanded its commercial reach, advanced its THP segment for a 2025 pilot, and secured new financing, while continuing to invest in growth initiatives.
-
Significant growth driven by innovative wound care platforms, expanding hospital penetration, and a strong sales network. Evidence-based outcomes support adoption, while a new value-based care model targets the large post-acute wound market. Q3 revenue hit a record $21.7 million.
-
Q3 2024 saw 35% year-over-year revenue growth to $21.7M and improved adjusted EBITDA, though net loss widened due to higher SG&A and interest expenses. The surgical segment delivered positive EBITDA, while THP investments continued ahead of a mid-2025 launch.
-
Q2 2024 revenue rose 28% year-over-year to $20.2 million, with record sales in soft tissue products and positive Adjusted EBITDA despite a net loss. Strategic investments continue in both surgical and post-acute wound care, with a major THP launch planned for 2025.
-
The meeting covered director elections, governance amendments, incentive plan approval, and auditor ratification. All proposals passed by majority or plurality vote, and no shareholder questions were raised.